Keyword: Xolair

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.

Facing stiff competition in asthma, Novartis’ Xolair can use all the help it can get to keep its blockbuster status. Could sinusitis be the cure?

AstraZeneca has released data showing its med's effects can last up to two years in severe asthma.

With blockbuster Xolair aging, Novartis is looking to usher in a successor to protect its sales. And it got one step closer this week.

Sanofi's Dupixent picked up its important asthma approval on Friday, setting the drug up for a multibillion-dollar peak sales boost.

Roche and Novartis want to keep aging Xolair competitive for as long as possible, and they recently took a big step forward in doing that.

Xolair, Nucala, Cinqair, Fasenra and Dupixent will need to take a 50% to 68% discount off the list price to achieve cost-effectiveness, says ICER.

It hasn’t been an easy summer for AstraZeneca in the respiratory department, but the British drugmaker has finally come up with a win.

Roche’s Xolair has seen competitors encroach on its territory over the last few years. But now, it’s ready to carve out a new niche of its own.